NYSE: NVO DEADLINE REMINDER: Berger Montague Reminds Nordisk A/S (NYSE: NVO) Investors of Important Class Action Lawsuit Deadline

04.09.25 17:36 Uhr

PHILADELPHIA, Sept. 4, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Novo Nordisk A/S. (NYSE: NVO) ("Novo" or the "Company") following the filing of a securities class action lawsuit. The lawsuit was filed on behalf of investors who purchased or otherwise acquired Novo securities from May 7, 2025 through July 28, 2025(the "Class Period").

A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto/Berger Montague)

Investor Deadline: Investors who purchased or acquired Novo securities during the Class Period may, no later than September 30, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Novo, headquartered in Denmark, is a global pharmaceutical company.

The lawsuit alleges that throughout the Class Period, the Company made false and misleading statements regarding the impact of compounded GLP-1 drugs. Specifically, the Company allegedly understated the effect of the FDA's personalization exception that permits many patients to continue using compounded alternatives. Novo also overstated the likelihood that these patients would switch to its branded drugs like Ozempic® and Wegovy®. As a result of these misrepresentations, investors suffered significant losses.

If you are a Novo investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com

Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nyse-nvo-deadline-reminder-berger-montague-reminds-nordisk-as-nyse-nvo-investors-of-important-class-action-lawsuit-deadline-302546698.html

SOURCE Berger Montague

Nachrichten zu Novo Nordisk (spons. ADRs)

Wer­bung

Analysen zu Novo Nordisk (spons. ADRs)

DatumRatingAnalyst
20.06.2019Novo Nordisk (spons ADRs) HoldDeutsche Bank AG
11.06.2019Novo Nordisk (spons ADRs) Equal WeightBarclays Capital
15.10.2012Novo Nordisk kaufenEuro am Sonntag
26.07.2012Novo Nordisk neutralExane-BNP Paribas SA
08.06.2012Novo Nordisk neutralSarasin Research
DatumRatingAnalyst
15.10.2012Novo Nordisk kaufenEuro am Sonntag
30.04.2012Novo Nordisk buyCitigroup Corp.
09.07.2007Novo Nordisk kaufen und liegenlassenGlobal Biotech Investing
14.12.2006Update Novo Nordisk A/S (Spons. ADRS): BuyCitigroup
08.12.2005Update Novo Nordisk A/S (Spons. ADRS): OutperformBear Stearns
DatumRatingAnalyst
20.06.2019Novo Nordisk (spons ADRs) HoldDeutsche Bank AG
11.06.2019Novo Nordisk (spons ADRs) Equal WeightBarclays Capital
26.07.2012Novo Nordisk neutralExane-BNP Paribas SA
08.06.2012Novo Nordisk neutralSarasin Research
18.05.2012Novo Nordisk equal-weightMorgan Stanley
DatumRatingAnalyst
30.05.2012Novo Nordisk underperformCheuvreux SA
22.03.2012Novo Nordisk sellDeutsche Bank AG
22.03.2012Novo Nordisk reduceNomura
21.02.2012Novo Nordisk reduceNomura
30.01.2012Novo Nordisk reduceNomura

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novo Nordisk (spons. ADRs) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen